SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor unfavorable primary chemosensitivity and incomplete debulking surgery.

Patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery.

- Percentage of patients operated with late complete debulking surgery after receiving 3 additional cycles of randomized chemotherapy (expected increase from 5% in the control arm to 20%)% in the experimental arm), - Overall survival improvement by 49% (HR = 0.61) in the whole population translating in an improvement in median OS from 20 months (control arm) to 32.8 months (experimental arm) with a 1:1 randomization

- Overall response rate according to RECIST V1.1 in the whole population (see appendix 4), - Progression-free survival in the whole population, - Percentage of patients treated with a subsequent maintenance treatment with a PARP inhibitor (%) in the whole population, - Progression-free survival and overall survival in these patients compared to those not treated with PARP inhibitor, - In the population of patients treated with bevacizumab: • Overall response rate according to RECIST V1.1 • Progression-free survival & overall survival according to RECIST V1.1 • Percentage of patients operated with a late complete debulking surgery (%), - Adverse events graded according to the NCI Common Terminology Criteria Adverse Event Version 5.0 (see appendix 3), - Quality of life questionnaires, - To determine the impact of patient beliefs, preferences and experiences on the decision-making process; endpoint: shared decision-making, - To determine the impact of the shared decision-making process on outcomes in the short- and medium-term; endpoints: satisfaction with care, satisfaction with decision, patient-doctor relationship, emotions, treatment beliefs, treatment adherence, and quality of life., - Percentage of patients with BRCA mutation (%), - Percentage of patients with BRCA wild-type HRD disease (%), - Percentage of patients with BRCA wild-type HRP disease (%), - Tests/assays used (names, proprietary), and percentage of each of them (%), - Incremental cost-utility ratio and incremental cost-effectiveness ratio, - Net financial impact over 5 years, - Percentage of patients operated with late complete debulking surgery, regardless of the number of chemotherapy cycles received

No related papers found yet.

France, Italy, Netherlands